共 50 条
- [1] AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumorsEJC SUPPLEMENTS, 2007, 5 (04): : 109 - 110Mita, A.Wang, D.Takimoto, C. H.Martin, D.Nguyen, L.Rasmussen, E.Storgard, C.LoRusso, P.
- [2] Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2010, 16 (11) : 3044 - 3056Mita, Alain C.Takimoto, Chris H.Mita, MonicaTolcher, AnthonySankhala, KamaleshSarantopoulos, JohnValdivieso, ManuelWood, LeslieRasmussen, ErikSun, Yu-NienZhong, Z. DonBass, Michael B.Le, NgocDiepLoRusso, Patricia
- [3] First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Rosen, L. S.Hong, D.Chap, L.Kurzrock, R.Garcia, A.Rasmussen, E.Nguyen, L.Hwang, Y.Storgard, C.Herbst, R. S.
- [4] AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancerCURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (04) : 487 - 495Neal, JoelWakelee, Heather
- [5] AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, Inhibits Angiogenesis in Models of Ocular Neovascular DiseasesINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2012, 53 (04) : 2170 - 2180Oliner, Jonathan D.Bready, JamesLinh NguyenEstrada, JuanHurh, EunjuMa, HongjinPretorius, JamesFanslow, WilliamNork, T. MichaelLeedle, Robert A.Kaufman, StephenCoxon, Angela
- [6] INTERIM RESULTS FROM A PHASE 1B STUDY OF SAFETY, PHARMACOKINETICS (PK) AND TUMOR RESPONSE OF THE ANGIOPOIETIN1/2-NEUTRALIZING PEPTIBODY AMG 386 IN COMBINATION WITH AMG 706, BEVACIZUMAB (B) OR SORAFENIB (S) IN ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2008, 19 : 154 - 154Hong, D.Gordon, M.Appleman, L.Kurzrock, R.Sun, Y.Rasmussen, E.Zhong, D.Le, N.Rosen, L.
- [7] OPEN-LABEL PHASE 1B STUDY OF AMG 386, A SELECTIVE ANGIOPOIETIN1/2-NEUTRALIZING PEPTIBODY, IN COMBINATION WITH SORAFENIB OR SUNITINIB IN ADVANCED RENAL CELL CARCINOMA (RCC): INTERIM RESULTSANNALS OF ONCOLOGY, 2010, 21 : 165 - 165Appleman, L. J.Gordon, M. S.Samlowski, W.Rasmussen, E.Sun, Y.Zhong, D.Friberg, G.Hong, D.
- [8] Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing PeptibodyMOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2641 - 2651Coxon, AngelaBready, JamesMin, HosungKaufman, StephenLeal, JuanYu, DongyinLee, Tani AnnSun, Ji-RongEstrada, JuanBolon, BradMcCabe, JamesWang, LingRex, KarenCaenepeel, SeanHughes, PaulCordover, DavidKim, HaejinHan, Seog JoonMichaels, Mark L.Hsu, EricShimamoto, GrantCattley, RussellHurh, EunjuNguyen, LinhWang, Shao XiongNdifor, AnthonyHayward, Isaac J.Falcon, Beverly L.McDonald, Donald M.Li, LukeBoone, TomKendall, RichardRadinsky, RobertOliner, Jonathan D.
- [9] Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3557 - 3565Herbst, Roy S.Hong, DavidChap, LinneaKurzrock, RazelleJackson, EdwardSilverman, Jeffrey M.Rasmussen, ErikSun, Yu-NienZhong, DonHwang, Yuying C.Evelhoch, Jeffrey L.Oliner, Jonathan D.Le, NgocDiepRosen, Lee S.
- [10] Clinical and Biologic Effects of the Angiopoietin 1/2 Neutralizing Peptibody Trebananib (AMG 386) in Acute Myeloid Leukemia PatientsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S126 - S126Eunice, Wang S.Gerald, Fetterly J.William, BradyWei, TanJessica, GreeneAllison, GaudyVigil Carlos, E.Jason, Mendler H.Michael, Becker W.Kristen, O'DwyerJane, LiesveldMeir, Wetzler